Weight loss stalled on Wegovy? Here's how to think it through

Is this a genuine plateau, or is the scale just lagging?

The first question worth sitting with is whether you're measuring the right things. Weight on a given morning can shift by a kilogram or more depending on water retention, salt intake, hormonal cycles, or simply what you ate the day before. A practical check: weigh yourself at the same time on the same day each week, in the same clothing, and compare four-week averages rather than day-to-day numbers. That single habit cuts out most of the noise.

If the four-week average has genuinely flatlined for six weeks or more, that's a real plateau and worth investigating. If it's moved even a small amount, the medicine is still doing something. The timeline for Wegovy to produce visible results is longer than most people expect at the start, and early enthusiasm can make a natural slowdown feel more dramatic than it is.

It's also worth remembering that the first weeks on Wegovy often show faster loss because of water and glycogen depletion, not fat loss alone. Once that initial drop settles, the rate nearly always slows. That's biology, not failure.

Why metabolism adapts, and why this matters on semaglutide

When you lose weight, your body requires fewer calories to maintain itself. This is called adaptive thermogenesis, and it's well-documented in obesity medicine. If you lose 10% of your body weight, your resting energy expenditure can fall by more than you'd predict from the weight change alone, because the body actively resists further loss. The result: the same eating pattern that produced a deficit three months ago now roughly matches what you burn. Progress stalls.

Semaglutide doesn't override this process. It reduces appetite and slows gastric emptying, which helps people eat less without conscious effort, as set out in the NHS patient information for semaglutide. But if calorie intake has crept back up (portion sizes, liquid calories, snacking that's become unconscious) the appetite-suppressing effect may not be compensating fully. This is especially common after several months on treatment, when the novelty of the medicine's effect wears off psychologically even if the pharmacology hasn't changed.

Protein intake and resistance exercise both slow the metabolic adaptation, because they help preserve muscle mass as weight falls. If your current routine is mainly cardio or low activity, that's a practical area to revisit with a dietitian or your prescriber.

Dose, duration and what the evidence actually says about plateaus

In the STEP 1 trial, participants on 2.4 mg semaglutide achieved an average weight reduction of around 15% over 68 weeks, published in the New England Journal of Medicine. That average obscures a lot of individual variation. Some participants lost more, some less; and the rate of loss was not constant throughout the trial. Most participants saw the steepest decline in the first six months; later months produced smaller but continued progress.

If you're still titrating toward 2.4 mg, it's worth knowing that lower doses generally produce less appetite suppression. A prescriber may consider whether progressing the dose is appropriate for your situation. The MHRA has also approved a 7.2 mg dose for eligible adults, which trials suggest narrows the gap with the highest tirzepatide doses. Information about how overall weight loss results on Wegovy vary by dose and individual can help set realistic expectations.

Duration also matters. Some people see a secondary dip in progress around months four to six, followed by renewed loss once the dose has been at maintenance level long enough. If you want a closer look at what causes a Wegovy weight loss stall and how to work through one, that guide covers the most common reasons progress pauses and what can be done about each. Your prescriber is the right person to interpret which pattern applies to you.

When to speak to your prescriber, and what to bring to that conversation

A stall lasting more than four to six weeks, especially after reaching the 2.4 mg maintenance dose, is a reasonable prompt to contact your prescriber. This isn't an emergency, but it is a clinical conversation worth having rather than guessing at solutions independently.

Bring as much context as you can: your weight readings over the past month, any changes in your eating pattern or activity, whether side effects have changed, and any new medicines or supplements you've started. GLP-1 medicines can interact with oral contraceptives and some other medications, which affects how the whole treatment picture looks.

If you're considering whether Wegovy is still the right option, or curious about how it compares to other licensed treatments, the full Wegovy treatment guide covers the medicine's mechanism and licensed use, and you can also explore weight-loss treatment options more broadly. For context on what treatment costs include, the Wegovy cost page sets out what a private prescription covers beyond the medicine itself.

If you haven't yet started treatment, or you're thinking about switching providers for better clinical support, our prescribers review every consultation personally. You can start a free consultation and have your answers reviewed the same day by a named, GPhC-registered clinician.